Cardiology – Page 13

Oral Semaglutide in Type 2 Diabetes: Efficacy and Safety with and without SGLT2 Inhibitors from the SOUL Trial

By MedXY 08/17/2025

The SOUL trial demonstrates that oral semaglutide significantly reduces major cardiovascular events in type 2 diabetes patients, independently of concurrent SGLT2 inhibitor use, with a favorable safety profile.

Cardiology Specialties

Advancements in Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: Insights from the TRILUMINATE Pivotal Trial

By MedXY 08/17/2025

Transcatheter edge-to-edge repair (TEER) offers a safe, effective option to reduce tricuspid regurgitation severity, improve quality of life, and lower heart failure hospitalizations up to two years, including in patients with cardiac implantable electronic device leads.

Cardiology Specialties

Inclisiran Shows Promise for Adolescents with Homozygous Familial Hypercholesterolemia: Results from the ORION-13 Trial

By MedXY 08/17/2025

The ORION-13 trial demonstrates that inclisiran significantly lowers LDL cholesterol by 33.3% and is safe and well tolerated in adolescents with homozygous familial hypercholesterolemia, addressing an unmet pediatric treatment need.

Cardiology Clinical Updates General Surgery news Specialties

Renal Denervation Shows Sustained Blood Pressure Reduction and Safety Over 24 Months in SPYRAL HTN-ON MED Trial

By MedXY 08/17/2025

The SPYRAL HTN-ON MED trial demonstrates that renal denervation provides significant long-term reductions in both ambulatory and office systolic blood pressure with good safety, supporting its role in managing hypertension.

Cardiology news Specialties

Higher Risk of Major Gastrointestinal Bleeding with Edoxaban vs Warfarin After TAVR: Insights from the ENVISAGE-TAVI AF Trial

By MedXY 08/17/2025

The ENVISAGE-TAVI AF trial found that patients with atrial fibrillation undergoing TAVR had a higher incidence of major gastrointestinal bleeding when treated with edoxaban compared to warfarin, highlighting the importance of risk factor identification.

Cardiology Specialties

Edoxaban as a Safe and Effective Anticoagulant Early After Bioprosthetic Valve Replacement: Insights from the ENBALV Trial

By MedXY 08/17/2025

The ENBALV randomized trial demonstrates that edoxaban offers a potential safe and efficacious alternative to warfarin for anticoagulation within three months after surgical bioprosthetic valve replacement, with comparable thromboembolic event rates and a distinct safety profile.

Cardiology news Specialties

ADVANTAGE AF Phase 2: Evaluating Pulsed Field Ablation for Persistent Atrial Fibrillation Using Continuous ECG Monitoring

By MedXY 08/17/2025

The ADVANTAGE AF Phase 2 study demonstrates pulsed field ablation's safety and efficacy for persistent atrial fibrillation, introducing continuous cardiac monitoring to better assess arrhythmia burden and outcomes over one year.

Cardiology news Specialties

Optimizing Sedation for Pulsed-Field Ablation in Atrial Fibrillation: Results of the COOPERATIVE-PFA Trial

By MedXY 08/17/2025

This randomized trial compares sedation regimens for pulsed-field ablation in atrial fibrillation, finding remimazolam-ketamine deep analgosedation superior to propofol-opioid approaches in reducing hypoxemia and hypotension.

Cardiology Clinical Updates news Specialties

High-Dose Statins and Their Impact on the Progression of Small Abdominal Aortic Aneurysms: Insights from a 5-Year Danish Cohort Study

By MedXY 08/17/2025

This 5-year prospective cohort study reveals that high-dose statin therapy significantly slows abdominal aortic aneurysm growth and reduces the risks of repair, rupture, and death in men, suggesting benefits beyond traditional cardiovascular risk management.

Cardiology Clinical Updates news Specialties

Abelacimab vs. Rivaroxaban in Atrial Fibrillation Patients on Antiplatelet Therapy: Insights from the AZALEA-TIMI 71 Trial

By MedXY 08/16/2025

The AZALEA-TIMI 71 trial shows abelacimab, a novel factor XI inhibitor, reduces bleeding risk compared to rivaroxaban in atrial fibrillation patients on antiplatelet therapy, suggesting a safer anticoagulation alternative.

Cardiology Clinical Updates news Specialties

High-Risk Plaques in Non-Culprit Lesions: Comparative Outcomes After NSTEMI and STEMI

By MedXY 08/16/2025

This study examines the morphology of high-risk plaques in non-culprit coronary lesions among NSTEMI and STEMI patients and their impact on clinical outcomes, suggesting comparable prevalence of high-risk features but differing plaque characteristics between these groups.

Cardiology news Specialties

Enhancing Cardiovascular Risk Prediction and Outcomes with Coronary CT Angiography: Insights from the PROMISE and SCOT-HEART Trials

By MedXY 08/16/2025

Coronary CTA, guided by clinical risk models and advanced radiomic plaque analysis, improves prediction and prevention of myocardial infarction in patients with new-onset chest pain, particularly in those with low clinical likelihood of coronary artery disease.

Cardiology Diabetes & Endocrinology Nephrology Specialties

Semaglutide’s Impact on Cardiovascular Outcomes Across Chronic Kidney Disease Stages in Type 2 Diabetes: Insights from the FLOW Trial

By MedXY 08/16/2025

The FLOW trial demonstrates that semaglutide significantly lowers cardiovascular risks and mortality in type 2 diabetes patients with chronic kidney disease, independently of CKD severity.

Cardiology Clinical Updates news Radiology Specialties

Revolutionizing Acute Myocardial Infarction Diagnosis: Insights from a New Clinical Classification Using Cardiac Imaging

By MedXY 08/16/2025

A novel clinical classification incorporating cardiac imaging refines diagnosis of acute myocardial infarction, distinguishing spontaneous, secondary, and non-infarction cases, improving risk stratification and guiding targeted treatment.

Cardiology OB/GYN & Women's Health Specialties

Pregnancies Following Peri-Partum Cardiomyopathy: Insights from the ESC EuroObservational Research Programme

By MedXY 08/16/2025

This study analyses maternal and neonatal outcomes in subsequent pregnancies after peri-partum cardiomyopathy (PPCM), revealing lower than expected maternal risks and suggesting potential reclassification of pregnancy risk categories based on ventricular function.

AI Cardiology Specialties

Advancing Acute Coronary Syndrome Care: ECG-Based Machine Learning Enhances Risk Stratification

By MedXY 08/16/2025

A prospective study shows that machine learning models trained on 12-lead ECG features outperform HEART score in predicting mortality among chest pain patients, improving risk-based care precision.

Cardiology Critical Care news Specialties

C-Reactive Protein as a Prognostic Biomarker in Infarct-Related Cardiogenic Shock: Insights from the ECLS-SHOCK Trial

By MedXY 08/16/2025

Elevated CRP levels independently predict short-term mortality in acute myocardial infarction complicated by cardiogenic shock, with extracorporeal life support showing no survival benefit regardless of CRP levels or admission timing.

Cardiology news Specialties

Evaluating Low-Dose Carperitide for Acute Heart Failure: Insights from the LASCAR-AHF Trial and Nationwide Outcomes in Japan

By MedXY 08/16/2025

Low-dose carperitide shows no significant benefit on long-term outcomes in acute heart failure, with evidence from randomized and large-scale cohort studies suggesting possible increased short-term risks compared to nitrates.

Cardiology Specialties

Comparative Efficacy of Vascular Closure Strategies After TF-TAVI: Insights from ACCESS-TAVI and CHOICE-CLOSURE Trials

By MedXY 08/16/2025

Recent randomized trials compare suture/plug-based versus suture-only and pure plug-based vascular closure techniques after TF-TAVI, revealing differences in complication rates and hemostasis times.